Inhibition of homologous recombination (HR) is believed to be a transactivation-independent function of p53 that protects from genetic instability. Misrepair by HR can lead to genetic alterations such as translocations, duplications, insertions and loss of heterozygosity, which all bear the risk of driving oncogenic transformation. Regulation of HR by wild-type p53 (wtp53) should prevent these genomic rearrangements. Mutation of p53 is a frequent event during carcinogenesis. In particular, dominantnegative mutants inhibiting wtp53 expressed from the unperturbed allel can drive oncogenic transformation by disrupting the p53-dependent anticancer barrier. Here, we asked whether the hot spot mutants R175H and R273H relax HR control in p53-proficient cells. Utilizing an I-SceI-based reporter assay, we observed a moderate (1.5 Â ) stimulation of HR upon expression of the mutant proteins in p53-proficient CV-1, but not in p53-deficient H1299 cells. Importantly, the stimulatory effect was exactly paralleled by an increase in the number of HR competent S-and G2-phase cells, which can well explain the enhanced recombination frequencies. Furthermore, the impact on HR exerted by the transactivation domain double-mutant L22Q/W23S and mutant R273P, both of which were reported to regulate HR independently of G1-arrest execution, is also exactly mirrored by cell-cycle behavior. These results are in contrast to previous concepts stating that the transactivation-independent impact of p53 on HR is a general phenomenon valid for replication-associated and also for directly induced double-strand break. Our data strongly suggest that the latter is largely mediated by cell-cycle regulation, a classical transactivation-dependent function of p53.
INTRODUCTION
DNA double-strand breaks (DSBs) are the main toxic lesions produced by ionizing radiation and radio mimetic drugs but they can also arise endogenously upon V(D)J recombination, action of topoisomerases or when a replication fork runs into a singlestrand break. In addition to DSB repair by non-homologous end joining, homologous recombination (HR) is available during the S-and G2-phases of the cell cycle to relieve the cells from these toxic lesions. While the vast majority of breaks are faithfully repaired, incorrect repair of DSBs can result in chromosomal abberations such as translocations, deletions or duplications, which are believed to frequently contribute to carcinogenesis. 1, 2 The tumor suppressor p53, also referred to as the guardian of the genome, protects from oncogenic transformation in many different ways. Upon cellular stresses such as DNA damage, p53 is modified, for example, by ATM (ataxia telangiectasia mutated)-catalyzed phosphorylation on Serin 15, preventing its MDM2-mediated ubiquitination and accordingly degradation. As an activated transcription factor, p53 is able to induce the expression of a variety of genes that can halt cell-cycle progression or induce apoptosis, thereby either giving the cell time to repair their DNA damage or ultimately eliminating the damaged cell. In addition to its role as a transcription factor, p53 was described to directly suppress HR. 3, 4 Spontaneous HR frequencies measured between two mutated versions of a reporter gene, which require HR to recombine a functional reporter, were much lower in p53-proficient cells than in cells lacking functional p53. 5, 6 Repression by one to three orders of magnitude were observed, leading to the conclusion that p53 is a key regulator of HR. Similar results were observed with two mutated viral genomes that require HR for virus release. 7 A transactivation-independent role of p53 in suppression of HR was postulated, since a mutant form, impaired in the transactivation of target genes, retained its suppressive function on HR. 8, 9 Diverse mechanisms for the transactivationindependent inhibition of HR have been described. Wtp53 was shown to bind to Rad51 and Rad54 proteins, promoting inhibition of strand exchange. 10 --12 P53 specifically binds Holliday junctions, facilitates their cleavage 13 and was further shown to recognize mismatches in heteroduplex DNA intermediates, thereby proofreading repair by inhibition of imperfect HR attempts. 14, 15 The suppression of HR was also shown to be dependent on the interaction of p53 with RPA (replication protein A), possibly by sequestering RPA at the site of the DSB. 9 Furthermore, p53 was reported to interact with the RecQ helicase BLM at stalled replication forks. Loss of p53 enhances the rate of sister chromatid exchanges in Bloom syndrome cells, but not in complemented or normal cells, 16, 17 implying that p53 does not inhibit HR steps like strand exchange per se. The transactivation-independent regulation of HR is believed to contribute to p53's role as central caretaker of the genome by restricting error-prone HR events that otherwise would lead to uncontrolled genetic rearrangements.
Transcriptionally active wild-type p53 (wtp53) is present as homo-tetramer and mutant variants of p53 with single amino-acid exchanges in the central DNA-binding domain but intact oligomerization domain are the most frequent mutations in human cancer. Unrestricted by the p53-MDM2 regulatory loop many of these mutants are expressed at relatively high levels and they can inhibit wtp53 from the residual, unperturbed allel by hetero-tetramer formation. 18 Inhibition of wtp53 by dominantnegative mutants is one of the key steps during carcinogenesis and amino-acid exchanges at positions R175, R248 and R273 are the most frequent events. 19 With regards to HR suppression, these mutants fail to demonstrate this function when expressed in p53-deficient cell lines. 20 Moreover, the oligomerization domain is, besides transactivation, also necessary for efficient HR repression 21 and dominant-negative p53 mutants were shown to stimulate spontaneous HR 6 as well as HR following replication fork stalling or ionizing radiation in p53-proficient cell lines by inhibiting endogenous wtp53. 22, 23 In this context, a specific mutant, R273P, still stimulated HR although it was unable to restrict wtp53-induced G1-arrest after irradiation, indicating that HR repression by wtp53 is independent of G1 checkpoint execution. However, compared with the number of studies performed in p53-deficient cells, only few studies investigated the interplay of wt and mutant p53 and none of these studies utilized the meganuclease I-SceI for specific DSB induction at the reporter construct.
Utilizing a chromosomally integrated I-SceI and green fluorescent protein (GFP)-based reporter system, we demonstrate that the influence on HR by dominant-negative p53 mutants and mutants previously reported not to influence the G1 checkpoint, is accompanied by changes in cell-cycle distribution. Moreover, the amount of cells in the HR competent S-and G2-phases exactly mirrors the results of the repair assays. Thus, our data strongly suggest that the primary mechanism by which p53 regulates I-SceI-induced HR is cell-cycle control rather than direct inhibition.
RESULTS

Cell-cycle dependency of HR
In order to study dominant-negative effects of p53 mutants upon HR, we utilized p53-proficient CV-1 cells (Figure 1a ) carrying a stably integrated copy of the GFP-based recombination substrate pGC 24 ( Figure 1b ) and p53-deficient H1299 to enable detection of wtp53-independent influences of the mutants. Cells were co-transfected with one of the different p53 variants in pcDNA3.1 together with pDSRed-I-SceI-GR 25, 26 (Figure 1c) , which induces single DSBs in the integrated reporter construct via its I-SceI nuclease moiety when activated by addition of the glucorticoid receptor (GR) ligand triamcinolone acetonite.
HR mainly occurs during the S-and G2-phase of the cell cycle, presumably because DNA end resection the mandatory initial step of HR is not efficient in G1. 27, 28 To confirm this cell-cycle dependency, DSBs were induced in a cell population enriched either in S/G2 after release from a transient block with aphidicolin or in the subsequent G1-phase. GFP expression indicating successful HR was measured after only 9 h in both cases to widely avoid contamination with cells that have entered the next cellcycle phase (Supplementary Figure 1a) . As expected, cells enriched in G1 showed widely reduced HR efficiency (Figure 1d ). The remaining HR activity observed in G1 cells is likely due to the residual S/G2 cells present in the G1-enriched population (Supplementary Figure 1c) .
In the following repair experiments aimed to monitor the impact of p53, HR activity (as read from GFP expression) was measured 48 --72 h after I-SceI-induction.
Repair inhibition is attenuated by dominant-negative p53 mutants Co-transfection of CV-1 cells with wtp53 inhibited repair to a level of 15% of the empty vector control (Figure 2 ) in line with previous observations. 20, 29 In contrast, co-expression with p53 hot spot mutant R175H or R273H stimulated HR up to a factor of 1.5 (Mann --Whitney t-test, Po0.001 for 175H vs empty vector control and P ¼ 0.0187 for 273H vs empty vector control, respectively). Expression of wtp53 in H1299 p53 null cells resulted in virtually complete inhibition of HR while, in contrast to CV-1 cells, the expression of mutp53 barely affected repair of I-SceI-induced DSBs. These findings indicate that the moderate stimulation of HR in CV-1 cells is due to dominant-negative inhibition of endogenous wtp53 and additionally, that the mutp53 proteins do not substantially influence repair on their own. Dominant-negative p53 mutants and suppression of G1-arrest We next asked whether expression of p53 variants significantly affects cell-cycle distribution to favor or disfavor HR. CV-1 and H1299 cells were co-transfected as before and subjected to cellcycle analysis 48 h later using the quantitative DNA marker FxCycle Far Red and anti-p53 staining to discriminate between cells that were positive or negative for ectopic p53 (Figure 3a ). In In the absence of a ligand, the glucocorticoid receptor (GR) moiety keeps the fusion protein bound to cytoplasmatic HSP90. Addition of triamcinolone acetonide results in rapid nuclear translocalization and DSB induction. 26 (d) CV-1 cells stably carrying the pGC reporter were transfected with pDsRed-I-SceI-GR and synchronized by treatment with aphidicolin. Upon release from the aphidicolin block, cells were enriched either in S/G2 or in subsequent G1. DSBs were induced for 9 h during passage of either cell-cycle phase (see Supplementary Figure S1 ). p53 modulates HR at I-SceI-induced DSBs T Rieckmann et al case of wtp53 expression, we observed for both cell lines a drastic reduction of cell numbers in the HR competent S-and G2-phases ( Figure 3b ). In contrast, the different subfractions that stained negative for ectopic p53 showed no marked variations in cell-cycle distribution. To the best of our knowledge, this is the first demonstration of a profound G1-arrest in the wtp53 overexpressing subpopulation in the setting of a reporter gene repair assay. This fact was hitherto not recognized, most likely due to only whole population analyses.
Western blotting verified high p53 protein levels after co-transfection in both cell lines (Figure 4a ) and immunofluorescence analysis confirmed co-expression of p53 in about 95% of DsRed-I-SceI-GR expressing cells, indicating that DSB repair after ISceI cleavage occurs in those cells that are also influenced by the p53 variants (Supplementary Figure S2) . Similarly, p21 expression revealed a pattern that well matches to the observed cell-cycle profiles. Expression of wtp53 was accompanied by strong p21 induction in both cell lines, despite the absence of exogenous DNA damaging agents other than co-transfected I-SceI (Figure 4a ). In contrast, the expression of p53 mutants 175H or 273H constantly resulted in an attenuated p21 response as compared with the vector control in p53-proficient CV-1 cells, whereas empty vector and both mutants lead to minimal, non-reproducible background signals in H1299 cells. To confirm the inhibitory effect upon p21 expression in CV-1, co-transfected cells were X-irradiated and p21 expression was determined by immunofluorescence microscopy in cells that were positive for DsRed-ISceI-GR. Overexpression of wtp53 did not increase the number of cells expressing p21 (Figure 4b ) but did increase p21 signal intensity per nucleus (Supplementary Figure S3) . In contrast, the Figure S2) , we stratified for Ds-Red-ISceI-GR expression before cell-cycle analysis at 48 h after co-transfection (Figure 5a ). This approach allows comparing wt and mutant p53 to the empty vector control, which was not possible when using ectopic p53 expression for stratification (Figure 3 ). In line with the previous observations, DsRed-positive cells co-transfected with wtp53 show for both cell lines the highest proportion of cells in G1 (Figure 5b; Supplementary Figure S4) . Strikingly, in accordance with p21 attenuation, the expression of mutp53-175H or -273H in CV-1 cells increased the fraction of HR competent S-and G2-phase cells compared with the empty control vector, which perfectly recapitulates the enhanced rate of HR observed previously (Figure 2 ). In contrast, expression of both p53 mutants failed to demonstrate any cell-cycle effect in p53-deficient H1299 cells.
Together, our results demonstrate (i) a substantial G1-arrest in cells overexpressing wtp53 that will largely contribute to the observed inhibition of HR and (ii) that mutp53 reduces a stressinduced G1-arrest only when it acts as a dominant-negative inhibitor of endogenous wtp53 but not in p53 null cells. Thus, the increase of S-and G2-phase cells likely explains the observed stimulation of HR in CV-1 cells expressing p53 cancer hot spot mutants 175H or 273H.
G1-independent suppression of HR Stress-induced G1-arrest is likely a transactivation-mediated function of p53. Impact upon recombination however has been linked to transactivation-independent effects of p53. 8, 9, 22, 30 Thus, we employed two p53 mutants that have been reported to affect HR independently of cell-cycle regulation. First, the L22Q/W23S double-mutant (in the following QS) within the N-terminal transactivation domain inhibits HR despite transactivation defects. 8, 9 Second, mutant 273P stimulates HR by inhibition of wtp53 in a p53-proficient background although it is, in contrast to mutant 175H, unable to suppress p53-dependent G1-arrest after irradiation. 22, 23 We found repair moderately reduced upon expression of QS in both, CV-1 and H1299 cells (Figure 6a ). Mutp53-273P stimulated HR in p53-proficient CV-1 cells but not in H1299 cells, indicating inhibition of endogenous wtp53 as observed for mutp53-175H and -273H (Figure 2) .
Cell-cycle control experiments performed as before showed for expression of the QS mutant a slight increase of G1 cells (Figure 6b ), which was linked to reproducible p21 induction in both cell lines albeit at a lower level compared with wtp53 ( Figure 4a ; sample QS and Supplementary Figure S5 ). No such p21 expression was observed upon co-transfection of the empty vector or any of the dominant-negative p53 mutants. This clearly demonstrates the potential of the QS double-mutant to induce p21 expression under the conditions of the reporter gene assay. A similar effect was reported for embryonic fibroblasts from transgenic mice expressing the equivalent murine mutant upon Doxorubicin treatment, indicating residual transactivation activity. 31 In contrast, mutp53-273P prevented a G1-arrest in p53-proficient CV-1 cells, but failed to affect cell-cycle distribution in p53-deficient H1299 cells (Figure 6b ) reminiscent of the dominantnegative mutants 175H and 273H (Figure 5b ). Therefore, both mutants QS and 273P fail to prove a cell-cycle independent influence of p53 on HR.
The obvious parallel regulation of repair and cell cycle prompted us to compare both parameters quantitatively. Figure 7 (see also Supplementary Figure S6 ) demonstrates a striking correlation between repair efficiency and the amount of cells in the recombination competent S-and G2-phases. Thus, activation of the p53 --p21-mediated G1-arrest in wtp53 expressing cells leads to an increase of the G1-phase population and a significant reduction in HR activity. The finding strongly supports the notion that the impact p53 has on HR is indirect and occurs via cell-cycle regulation.
DISCUSSION
The canonical HR pathway in mammalian cells is a constant focus of research and recently great progress has been achieved deciphering essential steps of the recombination process. Upstream regulation involving ATM, ATR-ATRIP, MDC1 and 53BP1, the resolution of recombination intermediates mediated by RMI1, TopoIII, BLM or Gen1 and, especially important for HR regulation, the initial process of DNA end resection implicating MRN, BRCA1, CtiP, ExoI and SIRT6 have recently been characterized. 27,28,32 --34 In addition, several lines of evidence also suggested a p53-mediated regulation of HR that is mechanistically independent of p53's major role as transcription factor controlling cellcycle regulation and cell death (reviewed in Bertrand et al. 3 and Gatz and Wiesmuller 4 ). HR at replication-associated as well as direct DSBs was reported to be suppressed by p53. For the latter, we confirm here an impact of p53, which, however, was found to be strictly coupled to cell-cycle regulation. Differing from most previous reports on p53 effects upon HR, we thoroughly considered three important aspects to monitor cell-cycle impact: (i) Control experiments were performed under exactly the same conditions as the recombination experiments without additional irradiation or DNA damaging compounds.
(ii) Backbone of empty control and p53-expression vector were exactly identical. (iii) Transiently transfected populations were stratified for transgene expression, because only cells expressing the I-SceI meganuclease will account for recombination. This approach demonstrated that the transgene expressing subpopulations clearly differed from the non-expressing cells of the same sample. The unstained, non-transfected fractions showed little variation and usually a high portion of cells in S/G2 (Figure 3; Supplementary Figure S7) . In contrast, the transgene expressing cells demonstrated marked differences, for example, a profound G1-arrest upon wtp53-I-SceI co-transfection compared with mutp53 and controls (Figures 3, 5b and 6b ). These differences can be easily masked when only whole populations are analyzed without stratifying for transgene expression. The fact that cells staining positive for the I-SceI fusion protein more readily accumulated in G1 indicates that these cells may suffer from stress due to the combination of p53-expression and I-SceI-induced DSBs. (Notably, thorough care was taken to minimize transfection stress per se by applying mild transfection conditions and early medium exchange to remove toxic transfection complexes.) We could show that for CV-1 cells, this G1-arrest is dependent on endogenous wtp53, as it is neutralized by hot spot p53 mutants 175H and 273H, as well as 273P. Together with the reduction in p21 expression, these observations verify a dominant-negative inhibition of the transactivation function of endogenous wtp53 in CV-1 cells (Figures 4  and 5b) . In contrast, both mutants have no marked effect in p53-deficient H1299 cells, for neither recombination nor cell-cycle progression. The strict correlation between the number of cells in S/G2 and recombination frequencies (Figure 7 ; Supplementary Figure S6 ) demonstrates that p53 variants can only exert minimal impact on HR besides shuttling cells into recombination competent or non-competent phases, respectively. Importantly, the correlation included also the transactivation impaired p53 double-mutant QS and mutant 273P, both of which were previously reported to restrict HR independently of the G1-arrest. 8, 22, 23 In CV-1 cells, expression of the QS mutant may amplify the p53 wt function as QS/wt heterodimers are less prone to MDM2-mediated degradation 31, 35, 36 (and correspondence 37 ). However, the induction of p21 and the G1-arrest in p53-deficient H1299 cells (Figures 4 and 6b) illustrate a significant residual transactivation activity of the QS mutant confirming previous observations. 31 Although co-expression of wtp53 results in the most pronounced G1-arrest, cell-cycle effects alone may not be sufficient to explain the extent of recombination inhibition, especially in H1299 cells where repair is virtually absent (Figures 2 and 6) . A minority In conclusion, the data presented here confirm the impact of p53 on HR at frank DSBs, but strongly challenge the established view that a main portion of this regulation is mediated by transactivation-independent mechanisms. We find effects on I-SceI-induced HR strictly associated with cell cycle and, in opposition to previous concepts, suggest that direct regulation of HR may not significantly contribute to p53's function in protecting against genomic instability and cancer development. It has to be noted that the p53-mediated protection from replication-associated damage, which is also highly important in the context of carcinogenesis, may be mechanistically distinct from the repair of directly induced breaks. Even so, in the light of the results presented here, it needs to be critically readdressed in future studies to what extend the protection of stalled or collapsed replication forks from excessive HR is a truly transactivation-independent function.
MATERIALS AND METHODS
Cells and cell culture
Untransformed primate CV-1 cells (African green monkey epithelial kidney cell line; ATCC CCL-70, Wesel, Germany) were grown in Dulbeccos p53 modulates HR at I-SceI-induced DSBs T Rieckmann et al modified eagle medium (DMEM) (Invitrogen) supplemented with 5% fetal bovine serum (Pan Biotech, Aidenbach, Germany). The human non-small cell lung cancer cell line H1299 (ATCC CRL-5803) was grown in Dulbeccos Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (Biochrome AG, Berlin, Germany). For maintenance of chromosomal reporter pGC 24 puromycin (Invitrogen) was supplemented at 10 mg/ml for CV-1 and 1.5 mg/ml for H1299, respectively.
Homologous recombination
Clones of CV-1 and H1299 cells containing stably integrated copies of the gene conversion substrate pGC were transfected using FugeneHD (Roche, Mannheim, Germany) according to the manufacturer's instructions. Co-transfections were performed with the pDsRed-I-SceI-GR expression vector together with wt or different mutant p53 cDNA, all cloned into the eukaryotic expression vector pcDNA3.1 (Invitrogen). Correct sequence of all p53 constructs was verified by DNA sequencing.
Six hours post-transfection, the medium was exchanged for fresh medium supplemented with 10 À7 M triamcinolone acetonide for efficient nuclear translocation of the DsRed-I-SceI-GR fusion construct as described. 26 At 48 --72 h post-transfection, the cells were assessed for expression of GFP by flow cytometry.
All results are given as relative repair normalized to the recombination efficiency of cells that were co-transfected with empty pcDNA3.1 vector. For H1299 cells, all individual results were directly normalized to transfection efficiency using the equation 'GFP-positive cells/(GFP-positive cells þ DsRed-positive cells),' since red fluorescence from high expression of DsRed-I-SceI-GR in these cells could be directly monitored by flow cytometry (see Figure 5a and Supplementary Figure S2 ). This normalization was not possible for CV-1 cells due to a weaker expression of the DsRed-ISceI-GR fusion protein. As a control, transfection efficiency of CV-1 cells as measured by co-transfection with pEGFP and the utilized pcDNA3.1-p53 variants was not influenced by expression of either wt or mutant forms of p53.
Cell-cycle analysis
At 48 h post-transfection, CV-1 cells were fixed in À20 1C cold EtOH for 10 min at 4 1C and then washed once with washing buffer (phosphatebuffered saline (PBS); 0.1% Tween20 (Sigma, Steinheim, Germany)) before blocking for 30 min in blocking solution (PBS; 0.5% bovine serum albumin (PAA, Pasching, Austria); 0.1% Tween20). Subsequently, cells were incubated for 1 h at room temperature (RT) with anti-DsRed antibody in blocking solution, washed three times before incubation with the secondary antibody and were again washed three times followed by counterstaining with the quantitative DNA marker FxCycle Far Red stain (Invitrogen, Darmstadt, Germany). After gating of DsRed-positive and negative subpopulations, differential cell-cycle distribution for each gate was monitored by flow cytometry. Data were analyzed using ModFit LT flow cytometry modeling software (Verity Software House, Topsham, ME, USA).
H1299 cells that express sufficiently high DsRed-I-SceI-GR levels were fixed with 4% formaldehyde for 10 min at RT, briefly washed in PBS; 0.1% Tween20, permeabilized in PBS; 0.2% Triton X-100 (Serva, Heidelberg, Germany) and counterstained with FxCycle Far Red stain for DNA content.
For p53 staining, both cell lines were fixed in PBS; 4% formaldehyde and permeabilized in PBS; 0.2% Triton X-100 before blocking and immunostaining as described above.
Immunofluorescence
Cells grown on glass coverslips were fixed in PBS; 4% formaldehyde for 10 min and permeabilized in PBS; 0.2% Triton X-100 before blocking for 30 min in PBS; 0.5% bovine serum albumin; 0.1% Tween20. Subsequently, cells were incubated for 1 h at RT with the primary antibody in blocking solution, washed three times before incubation with the secondary antibody and were again washed three times before mounting with Vectashield mounting medium (Vector Laboratories, Peterborough, UK) and inspection using a Zeiss Axioplan 2 fluorescence microscope (Zeiss, Jena, Germany).
Western blot
